---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-001925"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2021-09-29T23:59:59+00:00"
generated_at: "2026-06-29T00:42:53.221065+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences appoints Ran Zheng to board of directors

## Summary
- Board increased from 5 to 6 directors; Zheng appointed Class I director and to Nominating Committee.
- Zheng receives $40,000/yr board cash compensation plus $4,000/yr committee cash compensation.
- Initial grant of 44,000 non-qualified stock options, vesting over 3 years starting Oct 1, 2022.
- Zheng brings 25+ years biotech experience, most recently CEO of Landmark Bio and CTO at Orchard Therapeutics.
- Press release issued Sep 29, 2021; option exercise price = closing price on Oct 1, 2021 grant date.

## SEC filing metadata
- accession: 0000950170-21-001925
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2021-09-29T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000095017021001925/0000950170-21-001925-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000095017021001925/crbu-20210924.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-001925
- JSON: https://secwatch.observer/filing/0000950170-21-001925.json
- Plain text: https://secwatch.observer/filing/0000950170-21-001925.txt

## Key facts
- Executive change
  Ran Zheng was appointed as Class I Director at Caribou Biosciences, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On September 24, 2021, the Board of Directors (the “Board”) of Caribou Biosciences, Inc., a Delaware corporation (the “Company”), increased the size of the Board from five to six directors and unanimously agreed to extend an offer to Ran Zheng to serve as a Class I director of the Company, which offer Ms. Zheng accepted on September 24, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000095017021001925/0000950170-21-001925-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.